In BC, although the serum and tissue levels of TFF1 are typically overexpressed [49], many clinical studies have also reported that TFF1 deficiency increases tumorigenicity of human breast cancer cells, and TFF1 expression in BC has an effect on good clinical outcomes for patients [50, 51]. This evidence concerns the gene TFF1 and breast cancer.